左旋多巴/卡比多巴联合恩他卡朋治疗帕金森病的临床研究  

Clinical study of levodopa/carbitopa combined with entacapone in treatment of Parkinson’s disease

作　　者：马丽丽 张莉 吴怡颖 MA Li-li;ZHANG Li;WU Yi-ying(Department of Neurology,Yongcheng General Hospital,Yongcheng,Henan 476600,China)

机构地区：[1]永煤集团总医院神经内科,河南永城476600

出　　处：《医药论坛杂志》2022年第13期49-52,共4页Journal of Medical Forum

摘　　要：目的分析帕金森病应用左旋多巴/卡比多巴联合恩他卡朋治疗的临床疗效及安全性。方法选取2019年1月—2020年12月永煤集团总医院收治的84例帕金森病患者,采用随机数字表法分为两组,对照组42例采用左旋多巴/卡比多巴治疗,研究组42例加用恩他卡朋治疗,比较两组临床疗效。结果研究组治疗后总有效率95.24%,高于对照组的73.81%,差异有统计学意义(P<0.05);两组治疗后UPDRS评分均下降,5-HT水平均升高,且研究组UPDRS评分下降幅度及5-HT水平升高幅度均大于对照组,差异有统计学意义(P<0.05);两组治疗后白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)及超敏C反应蛋白(hs-CRP)炎性因子水平均显著降低,且研究组炎性因子水平IL-6(0.79±0.23)μg/L、TNF-α(18.76±3.29)μg/L及hs-CRP(3.28±0.75)μg/L,均低于对照组(P<0.05);经治疗后两组GSH-Px和SOD指标均升高,MDA降低,且研究组GSH-Px和SOD分别为(254.76±39.83)IU/L和(73.75±9.42)IU/mL,高于对照组的(217.58±32.76)IU/L和(65.48±8.31)IU/mL,MDA为(4.05±0.67)mmol/mL,低于对照组的(5.19±0.98)mmol/mL,差异有统计学意义(P<0.05);左旋多巴/卡比多巴联合恩他卡朋治疗研究组出现1例头晕、1例恶心呕吐、2例皮疹以及1例腹泻,不良反应总发生率为11.90%,左旋多巴/卡比多巴治疗对照组出现1例头晕、2例恶心呕吐、1例皮疹,不良反应总发生率为9.52%,两组比较无统计学意义(P>0.05)。结论左旋多巴/卡比多巴与恩他卡朋联合应用,能够有效改善帕金森病患者病情,提升其5-HT水平,减轻炎性反应,改善氧化应激状况,临床疗效确切,且不良反应少,安全性高,值得推广。Objective To analyze the clinical efficacy and safety of levodopa/carbitopa combined with entacapone in the treatment of Parkinson’s disease.Methods Eighty-four patients with Parkinson’s disease admitted to our hospital from January 2019 to December 2020 were selected and divided into two groups by random number table method.The control group(n=42)received levodopa/carbitopa treatment,and the research group(n=42)added entacapone treatment on the basis of the control group.The clinical efficacy of the two groups was compared.Results The total effective rate of the study group was 95.24%,which was higher than that of the control group(73.81%),and the difference was statistically significant(P<0.05).After treatment,UPDRS score decreased and 5-HT level increased in both groups,and the decreasing amplitude of UPDRS score and the increasing amplitude of 5-HT level in the study group were greater than those in the control group,with statistical significance(P<0.05).After treatment,the levels of IL-6,TNF-αand hs-CRP inflammatory factors were significantly decreased in both groups.The levels of inflammatory cytokines IL-6,TNF-αand hs-CRP in the study group were lower than those in the control group(P<0.05).After treatment,the levels of GSH-Px and SOD in the two groups increased,while the levels of MDA decreased.In the study group,the levels of GSH-Px and SOD were(254.76±39.83)IU/L and(73.75±9.42)IU/mL,respectively.Higher than(217.58±32.76)IU/L and(65.48±8.31)IU/mL in the control group,the MDA level was(4.05±0.67)mmol/mL,lower than(5.19±0.98)mmol/mL in the control group(P<0.05).1 case of dizziness,1 case of nausea and vomiting,2 cases of rash,and 1 case of diarrhea were found in the levodopa/carpacone combined with entacapone treatment group,with an overall incidence of 11.90%,and 1 case of dizziness,2 cases of nausea and vomiting,and 1 case of rash in the levodopa/carpacone treatment group,with an overall incidence of 9.52%.There was no significant difference(P>0.05).Conclusion The combined application of levo

关 键 词：左旋多巴 帕金森病 恩他卡朋 卡比多巴 治疗效果 安全性 

分 类 号：R742[医药卫生—神经病学与精神病学]